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Introduction 
Programmed death-1 (PD-1) is a CD28-family protein receptor, composed of 288 amino 
acids, that is expressed on the surface of B and T-cells (Riley 2009). Its main purpose is the 
regulation of the immune system, primarily through the process of peripheral tolerance. Through 
this mechanism, self-reactive T-cells that stochastically pass through self/non-self selection in the 
thymus and progress to peripheral circulation get deactivated into a state called T-cell anergy. In 
this state, cell proliferation and cytokine secretion is arrested. PD-1 is one such means of regulation, 
ensuring the prevention of self-reactive immunity and maintenance of T-cell homeostasis 
(Patsoukis, et al. 2012). Extensive research conducted on PD-1 and other receptors such as CTLA-4 
has found that the PD-1 upregulation mechanism causes T-cell exhaustion and anergy, or even 
apoptosis during chronic viral infection. The PD-1 receptor is made of an N-terminal 
immunoglobulin-V type domain, a 20 amino acid stalk, a trans-membrane domain, and a 
cytoplasmic tail with tyrosine signaling motifs (Riley 2009). PD-1 is activated by its ligands, PD-L1 
and -L2, which are on antigen-presenting cells. As seen in Figure 1, when they bind to PD-1, the 
protein inhibits the PI3K/Akt signaling pathway and affects T-cell activity.  
During chronic viral infections such as HIV or 
hepatitis C, the ability of cells to secrete cytokines and 
replicate is often impaired, a condition called T-cell 
exhaustion (Petrovas, et al. 2006). Particularly in the 
case of HIV, where the virus infects T-helper (TH) cells 
that are critical for promoting the immune response, 
cytotoxic T (Tc) cells are weakened due to the lack of TH support despite high viral load in the blood 
stream. Research has shown that during chronic viral infections, PD-1 becomes highly upregulated 
1: PD-1 and CTLA-4 target distinct signaling molecules 
but both ultimately inhibit Akt activation (Riley 2009) 
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on T-cells and contributes to T-cell suppression through the same mechanism as peripheral 
tolerance (Muthumani, et al. 2011). This correlation has become so well established that higher PD-
1 expression is now considered a marker of decreased homeostatic and antigen-induced 
proliferation in T-cells (Chomont, et al. 2009).  
One of the central pillars of human immunodeficiency virus (HIV) research has been 
centered on the phenomenon of ‘HIV controllers’. These individuals have a genetic ability to resist 
HIV infection and, despite exposure to the virus, have anti-HIV antibodies or viral load lower than 
detectable levels even months afterwards. In studies of their immune response, the controllers 
were found to have much lower levels of PD-1 and CTLA-4 than HIV sufferers. Studies have 
suggested that these lower levels allow the controller’s immune system to remain active and 
control viral progression (Baker, et al. 2009).  
Due to its protective effect in HIV controllers and potential in pharmaceutical anti-viral 
therapies, the path through which PD-1 affects T-cell exhaustion has become the center of 
research. The use of anti-PD-L1 antibody blockades in mice has been shown to restore T-cell 
function while reducing viral load (Day, et al. 2006).  More specifically, studies found that the PD-1 
pathway blockade created an increase in Tc cells that were able to overcome exhaustion and 
secrete cytokines (Walker and Kaufmann 2009).  
This paper will discuss three research articles exploring “Death and All Its Friends” or rather, 
the role of Programmed death-1 and similar receptors in arresting T-cell activity during chronic viral 
infection and attempt to shed light on the little known mechanism behind these effects. Following 
my analysis and synthesis of the three papers, I will suggest future experiments to explore and 
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develop the use of receptor blockades in anti-viral therapy to complement drugs that suppress the 
virus with treatment that maintains the strength of the immune system.  
Differential Association of Programmed Death-1 and CD57 with Ex Vivo Survival of CD8+ T-cells in 
HIV Infection (Petrovas, Chaon, et al. 2009) 
 In this paper, Petrovas et al. explore the roles of PD-1 and CD57 (a cell adhesion molecule) 
in apoptosis. They found that PD-1 is linked to increased spontaneous and C95/Fas-induced 
apoptosis in HIV-infected patients, decreasing the efficacy of the immune system. This correlation 
was reduced in cells with high expression of CD57. However, they found that there was no 
correlation between PD-1 expression and secretion of cytokines, contrary to conventional evidence 
linking PD-1 to T-cell exhaustion.  
With blood collected from HIV+ individuals, the authors analyzed cell sensitivity to apoptosis 
using polychromatic flow cytometry with fluorescent-conjugated monoclonal antibodies for various 
markers to differentiate between cells in the sample. In this process, a sample of cells is inserted 
into the FACS (fluorescence activated cell sorter) machine. Since cells have already been 
fluorescently tagged for receptors of interest, the FACS analyzes the sample and sorts each cell 
based on high/dim/low expression of the selected receptors, graphed on a logarithmic scale. This 
allows researchers to analyze an entire population of cells highlighting specific characteristics. In 
this case, cells are selected for CD27 and CD45RO to identify memory T cell subsets. CD27 is a tumor 
necrosis factor (TNF) receptor that is necessary for T-cell immunity and is involved in apoptosis 
when bound by apoptosis-regulatory protein, SIVA (National Center for Biotechnology Information 
2012). CD45 is a receptor common to all leukocytes and was used as the primary way to identify 
immune cells. Apoptosis was measured using cell culture in presence or absence of annexin V and 
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an anti-caspase 3 antibody. Annexin V is often used as a probe for phosphatidylserine, which is 
expressed on the surface of cells during apoptosis. Similarly, caspase-3 is another protein associated 
with apoptosis. During their studies, Petrovas et al. found that the presence of annexin V was 
consistently associated with the presence of caspase-3. This shows that the apoptosis was caspase-
3 mediated.  
The authors first used naïve T-cells (CD27HCD45ROL) to set a gating scheme for expression of 
PD-1, as can be seen in Figure 2A across the top. As CD8+ cells matured (shown from left to right in 
Figure 2B), sensitivity to both spontaneous and CD95/Fas-mediated apoptosis increased, as shown 
by increased presence of both annexin V and active caspase-3. In the bar graph of Figure 2B, the 
various cell phenotypes are organized according to apoptosis, spontaneously or in the presence of 
CD95/Fas. This is one shortcoming in the methodology. In measuring cell death, they assume that 
all the apoptosis that occurs in the presence of C95/Fas is protein-mediated. However, they 
overlook the possibility that some of the apoptosis under those conditions could still be 
spontaneous. This makes the number for C95/Fas-induced apoptosis artificially inflated since it 
potentially includes both forms of apoptosis that took place in the presence of C95/Fas. In Figure 
2C, this data is combined with the expression rates for PD-1. PD-1HCD27LCD45ROH/D cells had the 
greatest sensitivity to apoptosis, especially C95/Fas-induced. In agreement with commonly 
accepted mechanisms, there was a higher percentage of PD-1H CD8+ cells in patients with higher 
HIV+ viral load. Furthermore, authors found that there were fewer PD-1HCD27LCD45ROHCD8+ T-cells 
in patients undergoing Highly Active Anti-Retroviral Therapy (HAART) compared to untreated HIV 
patients. They also found that PD-1HCD27LCD45ROH cells from the same donors, undergoing the 
treatment, were more susceptible to C95/Fas-mediated apoptosis, an interesting correlation that 
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2: PD-1 is a primary indicator of ex vivo apoptosis of CD8+ T-cells in HIV Infection. A: Flow cytometry gating of CD8 T-cells 
expressing L, D, or H levels of PD-1. B: Flow cytometry plots with annexin V binding and caspase 3 levels in CD8 T-cells from 
HIV=positive donor. C: Percentage of cells undergoing apoptosis in relation to PD-1 expression. Apoptosis was measured based  
on binding of annexin V or expression of active caspase 3 (Petrovas, Chaon, et al. 2009).  
 
the authors weren’t able to explain. It would be fascinating to see why the anti-retroviral drugs 
cause this increased susceptibility in T-cells.  
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However, here is another shortcoming of this paper. The data for HAART-recipients and 
untreated patients are pooled for the charts and data analysis. While the authors include their 
observations from the data of the subgroups, they overlook those differences in their data 
publication, a significant oversight. In the chart, they should have shown the two groups separately 
in every category since the effects of HAART on the PD-1 pathway have not been established yet. By 
pooling them, they assume that there is no difference between both samples, yet they prove their 
own assumption wrong when they observe the differences in susceptibility to C95/Fas apoptosis 
between treatment groups.  
The next step that the Petrovas et al. took was studying the association of PD-1 and CD57 
with the different forms of apoptosis using flow cytometry. Figure 3A shows the amount of CD57 as 
a function of time or maturation of T-cells. As can be seen, CD57 is markedly upregulated over time, 
progressing from 0.43% in younger cells to 60.1% in memory cells. In the lower panel of 3A, the 
authors make the observation that the two receptors peak at opposite ends of the maturation 
spectrum, with CD3 being highest in young cells and CD57 highest in memory cells. They conclude 
their analysis with this; however, they should have included more analysis of this data to draw 
conclusions about why PD-1 peaks earlier and then decreases, as well as why the presence of PD-1D 
lingers after the fading of the PD-1H phenotype.  In Figure 3B, the sensitivity to apoptosis is 
examined in the same combinations of PD-1 and CD57 cells. As can be seen, PD-1HCD57L cells 
showed the highest sensitivity to both spontaneous and CD95/Fas-mediated apoptosis except in 
CD27HCD45ROH cells. In that case, the PD-1HCD57H cell count is significantly higher. Furthermore, 
apoptosis rates for the PD-1LCD57H subgroup are fairly constant throughout T-cell types. The 
researchers do not explore this further, providing no explanation for these phenomena. Regardless 
of this question, the data clearly shows that PD-1 and CD57 have a differential association with 
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3: Differential association of PD-1 and CD-57 with spontaneous and CD95/Fas-mediated apoptosis. A: In the upper 
panel, flow cytometry showing PD-1 vs. CD57 expression in the entire CD8 T-cell population as well as CD57 expression 
in the memory CD8 T-cell population. Lower panels show relative expression of PD-1 and CD57 in relation to 
maturation. B:  Upper panel shows expression of PD-1 in relation to CD57 at stages of maturation. Lower panel shows 
percentage of apoptotic memory CD8 T-cells with respect to PD-1 and CD57. (Petrovas, Chaon, et al. 2009) 
apoptosis, because CD57H is consistently associated with low amounts of annexin V or active 
caspace-3. 
Petrovas et al. then establish how many HIV-specific CD8+ T-cells express the PD-1HCD57L 
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subgroup that was associated with sensitivity to apoptosis in Figure 3, as opposed to the previous 
consideration of all CD8+ cells before. In Figure 4A, the authors analyze the HIV-specific CD8 T-cells 
and use a gating strategy to measure cytokine expression of IFN-γ, TNF-α, and IL-2, which were used 
to select virus-specific cells after stimulation. In the lower panel of Figure 4A, the relative 
percentages of cells expressing PD-1 and CD57 are shown based on the cytokines used to select 
group-antigen (gag) specific cells for either HIV or cytomegalovirus (CMV). The writers found that 
PD-1HCD57L was the most common HIV-specific T-cell found. PD-1LCD57H was consistently the 
lowest percentage among T-cells. This data was in line with existing research showing that in 
chronic viral infections, T-cells expressing high amounts of PD-1 become the dominant phenotype. 
However, in the right panel for CMV, there were slightly different results. PD-1LCD57L and PD-
1LCD57H were the highest expressed phenotype for specifically the IFN-γ and IFN-γ/TNF-α groups. 
On the other hand, cells expressing both IFN-γ and IL-2 expressed PD-1LCD57L or PD-1HCD57L. This 
leads us to believe that CMV-specific T-cells overwhelmingly express a PD-1L phenotype, in direct 
disagreement with existing research. The significance of this data is questionable considering the far 
smaller sample pool of CMV-specific cells than with the HIV-specific cells. Furthermore, the testing 
of CMV is strange since the article is about HIV. Its inclusion only serves to confuse the author’s 
conclusion that HIV and CMV cells both exhibit no association between PD-1 expression and 
cytokine production since the same trend of receptor and cytokine expression cannot be seen 
between HIV and CMV-specific T-cells. This difference could be due to the small sample size, making 
the result misleading. 
Using the same data, authors sought to compare the cytokine response between PD-1 
positive and negative cells. Figure 4B shows the pie chart illustrating the proportion of cells 
expressing each cytokine. Contrary to the extensive documentation suggesting the role of PD-1 in T-
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 that is not associated with the ability to produce cytokines. 
A: Flow cytometry plots showing expression of PD-1 and CD57 in Gag-specific T-cells identified by IFN- γ, IFN-γ/TNF-α, or 
IFN-γ/IL-2 production. Lower panel shows phenotypes of HIV and CMV specific T-cells with respect to PD-1 and CD57 
expression. B: Composition of HIV and CMV-specific T cell response in relation to PD-1 expression. Pie denotes total fraction 
corresponding to a given number of cytokine functions. Right panel shows MFI values of PD-1 for all combinations of 
cytokine response. Boxes represent interquartile range.  (Petrovas, Chaon, et al. 2009) 
cell exhaustion, including depressed cytokine secretion, the authors found that there was not a link 
between PD-1 expression and cytokine secretion for virus-specific cells. When comparing the pie 
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charts for both PD-1+ and PD-1- cells, one can see that there is no observable difference between 
cytokine expression, regardless if they are HIV or CMV-specific. In the right panel of Figure 4B, the 
authors show the MFI (mean fluorescence intensity) of PD-1 with a variety of cytokine 
combinations. They observe that no significant difference can be seen between cells specific for one 
virus, regardless of the cytokine combination tested. While their observation for HIV-specific cells is 
accurate, the same for CMV-specific cells is questionable because there is deviation for some of the 
cytokines combinations. Nevertheless, I think that it is less a result of actual difference and more 
due to the small sample size that the authors used. As a result, they should have disregarded their 
data for CMV and only concentrated on HIV-specific cells.  
Overall, Petrovas et al. found that PD-1 and CD57 were differentially associated with 
spontaneous and C95/Fas mediated apoptosis in HIV cells. This is significant because high 
expression of PD-1 is found to be the dominant phenotype in HIV-specific cells during chronic 
infection as the cells mature. These findings are in line with various existing papers. However, the 
data diverges from convention in terms of cytokine products. The authors find that there is no link 
between PD-1 expression and cytokine production in either HIV or CMV-specific cells. This is in 
direct contrast to papers explaining that PD-1 expression has been directly linked to T-cell 
exhaustion during chronic viral infection. One of the points to be considered in the methodology is 
the donor population size. The researchers collected blood from only 32 HIV+ donors and pooled 
the samples. However, as discussed earlier, these HIV+ donors consisted of a mix of those 
undergoing HAART as well as those that were untreated. Ten of the donors were still asymptomatic. 
Therefore, they cannot even really be considered sufferers of chronic HIV infection. The 
researchers’ choice to pool blood from patients in different stages of HIV infection for 
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experimentation was unfortunate. The authors should have ensured that their sample pool was 
either separated or was limited to either treated or untreated patients.  
Synergistic Reversal of Intrahepatic HCV-Specific CD8 T-cell Exhaustion by Combined PD-1/CTLA-4 
Blockade (Nakamoto, et al. 2009) 
 Nakamoto et al, study the role of PD-1 and CTLA-4 (cytotoxic T lymphocyte-associated 
antigen 4) in T-cell exhaustion during chronic hepatitis C (HCV) infection. Hepatitis C is a highly 
pathogenic virus that infects the liver and leads to chronic liver disease. As with other similar viral 
infections, PD-1 expression is upregulated on virus-specific T-cells. The authors cite previous papers 
that show that an in vitro PD-1 blockade results in restoration of effector function. However, in 
acute HCV infection, exhausted CD8 T-cells do not react to PD-1 blockade alone, suggesting the 
involvement of other mechanisms in the regulation of T-cells.   
To look for other mechanisms, they studied the CTLA-4 protein. Existing research showed 
that, in HCV-specific T-cells, CTLA-4 is upregulated in addition to PD-1. Due to this, Nakamoto et al. 
explored the use of a combined PD-1/CTLA-4 blockade to reduce T-cell exhaustion as a therapy for 
viral infection. For the study, blood from 47 HCV patients was collected, including 33 that were 
cirrhotic and undergoing a liver transplant and 14 that had chronic but stable HCV. The control 
groups consisted of ten seronegative patients (no detectable antibodies), four seropositive 
(detectable antibodies) but RNA-negative, and 6 with acute HCV. In the paper, the authors were 
really clear about their sample size and distinguished their various control groups which I 
appreciated in terms of research method; I will address this in more detail later in my paper. 
In their first experiment, shown in Figure 5, the authors used flow cytometry to study CTLA-
4 expression specifically in hepatic HCV-specific T-cells. In Figure 5A, they show the percentage of 
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5: CTLA-4 expression is increased in intrahepatic HCV-specific CD8 T-cells. A: %CTLA-4+ from 29 
C (chronic), A (acute), R (resolved), and N (negative control) HCV patients. B: CTLA-4 expression 
in tetramer
+ 
T-cells specific for HCV epitopes and other viruses. C: Flow cytometry plots for 
tetramer
+ 
cells. Middle shows PD-1/CTLA-4 staining of gated tetramer
+ 
cells. On the bottom, 
cut off strategy based on isotype. D: FACS plots showing preferential expression of CTLA-4 in 
PD-1 
H
 cells and further cutoff strategy. E: Correlation between PD-1 and CTLA-4 expression in 
HCV-specific tetramer
+
 cells. Red circles are HCV-specific CD8 T-cells from HCV-infected liver 
and peripheral blood of acute patients. (Nakamoto, et al. 2009) 
CD8 cells positive for CTLA-4 within C (chronic patients), R (recovered patients), N (seronegative 
patients), and A (acute patients). As can be seen, R and N controls show very low expression of 
CTLA-4. Interestingly, in acute patients, peripheral blood lymphocytes (PBLs) with CTLA-4 are quite 
high, especially in comparison to PBLs in chronic patients. However, as the HCV infection 
progresses, one can see that levels of CTLA-4+ cells drop in the blood stream. Alternatively, there 
are very high levels of CTLA-4+ liver infiltrating lymphocytes (LILs), an extremely significant 
observation (p-value <0.0001).  
In Figure 5B, the researchers study the levels of CTLA-4 between HCV and other viral 
infections including influenza, Epstein-Barr virus (EBV), and CMV (cytomegalovirus). They measure 
CD8 cells that are tetramer+, a refolded peptide:MHC complex that is specific to a particular 
epitope. This 
technique allows 
scientists to quantify 
the number of T-
cells in a sample 
that target a 
particular antigen. 
The data shows 
that, in the blood, 
CTLA-4 levels 
remain about the 
same, but, in the 
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liver, a higher percentage of HCV-specific cells express the protein. This demonstrates that this 
observation is unique to HCV. In the lower panel of Figure 5B, the authors show the data arranged 
by the patient group. As expected, there is no significant difference between blood and liver CTLA-4 
levels in recovered patients; both are very low. But, once again, there is a very large difference 
between levels of CTLA-4+ T-cells in the liver versus blood of chronic HCV patients. Nakamoto et al. 
note that this contrasts with known levels of PD-1 expression in viral infection, where PD-1 is 
expressed highly in circulating lymphocytes as well.  
In Figure 5C, authors show flow cytometry dot plots of their gating strategy to visually 
demonstrate the difference between the T-cell populations, especially comparing the levels of 
CTLA-4 and PD-1 in row two. In the first row, one can see the small proportion of the virus-specific 
CD8 cells in the blood and the significantly higher percentage for HCV in the liver. When levels of 
CTLA-4 and PD-1 are compared, the researchers found that CTLA-4 is a barely expressed in the 
absence or low-expression of PD-1 (Figure 5C/D). Consequently, CTLA-4 is only significantly found 
on the chronic HCV-specific LILs and the acute HCV-specific PBLs; the cases in which PD-1 was 
expressed in higher proportions as well. This correlation led credence to the author’s hypothesis 
that CTLA-4 plays a role in the cell exhaustion mechanism along with PD-1. In Figure 5E, data shows 
that there is a strong correlation between PD-1 and CTLA-4 expression among all cells during acute 
infection (red circles indicate patients with acute infection). This confirms the notion that this 
upregulation of both receptors continues in the bloodstream until onset of chronic infection, where 
CTLA-4 and PD-1 dual-positive cells become sequestered in the liver. In terms of data, a similar 
chart, showing the correlation between PD-1 and CTLA-4 in LILs of chronic HCV patients, would 
have been beneficial. Having established the link between CTLA-4 and PD-1 expression in liver-
based CD8 T-cells of chronic HCV patients, the authors sought to test the effects of a blockade.   
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6: Intrahepatic HCV-specific T-cell dysfunction can be reversed synergistically by combined PD-1/CTLA-4 blockade.  
A: Effect of receptor blockade on HCV-specific cytokine production by T-cells from liver and blood. B: Flow cytometry 
plots showing 7 days of culture with NS3 or flu-peptides in the presence of isotype or blocking antibodies. On far left, 
plots show PD-1 and CTLA-4 expression in liver CD8 T-cells in vivo. (Nakamoto, et al. 2009) 
Figure 6 shows the results following CTLA-4/PD-1 receptor antibody blockade of HCV-
specific LIL and PBLs in culture medium. Following blockade with αPD-L1 and αCTLA-4, the cells 
were stimulated with viral peptides spanning the entire HCV pNS3 or flu matrix and then underwent 
intracellular cytokine staining to identify antigen specific IFN-γ or TNF-α expression. As can be seen 
in Figure 6A, there was little, if at all, production of cytokines with the isotype, PD-L1, or CTLA-4 
blockade. However, with antibodies to blockade both receptors in the presence of viral peptides, 
cytokine production for the pNS3 peptide jumped. This showed that the dual blockade was the 
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most effective. Interestingly, the dual blockade had little difference to single blockade in PBLs, 
which responded in small degrees to both individual and dual blockades alike. In CD4 cells, this 
pattern was not seen. The PD-L1 blockade actually produced the highest cytokine levels, even 
higher than the dual blockade. The blockade of just CTLA-4 was no higher than the isotype only 
group. This could indicate that the role of CTLA-4 on T-cell exhaustion is limited to CD8 cells. In 
Figure 3B, the flow cytometry plots for HCV as well as flu blockades are shown. Results for HCV are, 
of course, the same: dual blockade is the most effective at increasing cytokine production. 
Interestingly enough, with the flu, there was no increase in cytokines when a dual blockade was 
implemented. If anything, the production seems to have decreased by over half from 1.52% to 
0.59% of cells. This confirms the previous conclusion that PD-1 and CTLA-4 both have roles in T-cell 
exhaustion only in chronic hepatitis C infection.  
 Earlier in the paper (figure not shown), Nakamoto et al. established that the PD-
1HCTLA-4H cells also expressed high levels of the co-stimulatory molecule CD28, even more than in 
cells with either PD-1H or CTLA-4H. It is already known that, like PD-1, CD28 plays a role in T-cell 
anergy. However, unlike PD-1, it is a positive stimulatory molecule involved in T-cell activity. T-cell 
activation requires two signaling events: binding with antigen presented on dendritic cells as well as 
CD28:B7 interaction, to prevent the T cell from falling into an anergic state. 
 Due to this observation, the authors sought to clarify the role of CD28+ cells and see 
whether CD28 was required for the CTLA-4/PD-1 blockade to be effective. Figure 7 shows the 
results of this experimentation. Figure 7A shows the HCV NS3-specific T-cells once again, except this 
time those exclusive to IFN-γ. The populations of CD4-deprived lymphocytes were separated into 
one group with and one without CD28 subset depletion. As can be seen in this figure, even without 
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7: Functional restoration by PD-1/CTLA-4 blockade is CD28-dependent. A: Loss of HCV-specific CD8 T-cell IFN-γ response by 
CD28 depletion. LILs or PBLs were depleted of CD4 with or without CD-28 depletion and cultured for 7 days with a PD-
1/CTLA-4 blockade. Cells were examined for HCV-specific cytokine production by ELISPOT assay. B: CD28 expression in HCV-
specific cells relative to PD-1 and CTLA-4 expression. C: Effect of CD28-depletion on antigen-specific expansion with or 
without a PD-1 and/or CTLA-4 blockade, shown by CFSE dilution. (Nakamoto, et al. 2009) 
CD4 T-cells, the cytokine response was significantly higher with the dual CTLA-4/PD-L1 blockade. 
However, when CD28 was depleted, the effect of the blockade was much reduced in all three 
patients regardless of whether they were chronic or acute sufferers of HCV. The authors conclude 
that CD28 is therefore required for the blockade to be effective.   
 Nakamoto et al. then decided to study a specific epitope of the HCV virus, NSC-1073. Figure 
7B sets the background for the assay in ex-vivo conditions by showing the respective proportions of 
cells. As can be seen, 28% of the CD8 T-cells expressed CD28. 97.3% of the cells express PD-1, alone 
or with CTLA-4, and 20.5% of cells have CTLA-4 (all of these express PD-1 too). In the right-most 
graph, the numbers of cells expressing each receptor are compared to CD28 expression. The green 
line represents the number of PD-1+CTLA-4- cells (19.5% express CD28). The blue line shows PD-1-
CTLA-4- (12.2% express CD28) and the red line shows PD-1+CTLA-4+ cells (50% express CD28), clearly 
indicating a majority of cells positive for both receptors. These individual cell populations are 
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analyzed separately in Figure 7C.  Carboxyfluorescein succinimidyl ester (CFSE) dilution is used to 
track proliferation of T-cells in the presence of receptor blockades, with and without CD28. CFSE is a 
dye that stains lymphocytes. When lymphocytes divide, the concentration of CFSE in their daughter 
cells is cut in half. This allows researchers to use this dye to track proliferation of cells for several 
divisions. Due to this, cells in the upper quadrant of the dot plots are newer cells (with lower 
concentration of CFSE, an indicator of cell proliferation) that are still specific to the HCV 1073 
epitope. As can be seen, when the dual blockade is carried out, the proportion of new cells is 3.65%. 
This is compared to the 0.58% of CTLA-4 blockade alone and close to zero for the isotype or PD-L1 
blockade alone. However, when CD28 cells are depleted, the impact of the dual blockade results in 
only a 0.13% new HCV1073-specific cell population. This clearly shows that a dual CTLA-4/PD-L1 
blockade not only inhibits apoptosis, but also revives both cytokine secretion and proliferation of 
virus-specific T-cells in the HCV infection specifically. The authors also show how this process must 
be mediated by CD28 CD8 T-cells to have an effect. They further discuss how PD-1 inhibits the 
activation of T-cells through the CD-28 mediated phosphatidylinositol 3-kinase (PI3K) pathway and 
that CTLA-4 “activates the type II serine/threonine phosphatase PP2A, both leading to the inhibition 
of Akt phosphorylation” (Nakamoto, et al. 2009). As such, CTLA-4 directly competes with CD28 and 
reduces its mediation of PI3K-activation. In the presence of PD-1, CTLA-4 further inhibits the 
pathway.  
 Looking at the big picture, the authors confirm previous data that PD-1 impacts T-cell 
exhaustion; however, they prove that CTLA-4 has a crucial role in depressing the immune response 
to hepatitis C, but not to other viruses that they tested. Their finding regarding PD-1 directly 
contradicts Petrovas at al, by showing that PD-1, with or without CTLA-4, does inhibit antigen-
specific cytokine (TNF-α and IFN-γ) secretion in T-cells.  
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 In further comparison to the first paper by Petrovas et al, this paper was far clearer in its 
analysis and description of figures. Figure 5 is an example of how Nakamoto et al. were very 
thorough in keeping extensive track of their control populations and establishing a baseline for 
expression. Rather than pool the data together, they separated groups that had chronic, acute, or 
resolved expression, in addition to being seronegative or positive. This attention to detail makes the 
data in the second paper more valuable when they draw conclusions based on a specific population 
profile. For some of their later experiments, they also took specific patients and analyzed their 
lymphocyte populations independently, again keeping careful track of their state of infection. This 
methodology was very thorough and minimized potential critique of their conclusions. One of the 
few insufficiencies was that some of the later figures (6 and 7) rely on only a few patients to 
establish their conclusions. While this analysis on a patient-specific basis was also a strong aspect of 
the paper, the authors should have carried out this separate analysis for more individuals. I 
recognize that conducting the data collection for every patient is difficult, but a sample size of only 
three (in Figure 7) is not enough to draw conclusive results. This is a significant shortcoming, 
especially considering that, despite having data from only one acute patient, they assume that the 
exhibited effects of CD28 are universal among other acute sufferers. 
 Despite this flaw, this paper is an excellent example of effective and clear research 
methods. Nakamoto et al. provide data that sheds important light on the therapeutic potential of a 
receptor blockade of CTLA-4 and PD-1 to reduce the impact of exhausted cells in chronic sufferers 
of viral infection. This blockade would supplement the use of anti-retroviral drugs, which slow viral 
replication, by reducing the exhaustion of the CD8 T-cells that combat the virus. With increased 
proliferation and cytokine secretion, the patient would be able to more effectively fight the disease. 
They clearly discuss how the two receptors redundantly cause T-cell exhaustion, but that “immune 
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exhaustion at the site of antigen expression may be reversed by combined inhibitory receptor 
blockade” (Nakamoto, et al. 2009). This observation, shared by with Petrovas et al, illuminates a 
potential path for therapy research and development.  
HIV-Mediated Phosphatidylinositol 3-Kinase/Serine-Thereonine Kinase Activation in APCs Leads to 
Programmed Death-1 Ligand Upregulation and Suppression of HIV-Specific CD8 T-cells 
(Muthumani, et al. 2011) 
Muthumani et al. explore the role of HIV in depressing T-cell function during chronic HIV 
infection. However, in contrast to the previous two papers, this lab takes a very different approach 
to the problem. Rather than look at the role of HIV infection on upregulation of PD-1 in T-cells, they 
look at the role of HIV infection on antigen presenting cells’ (APC) expression of PD-L1 and PD-L2. 
They start their project on the basis that the administration of antibodies that interfere with 
the binding of PD-1 to its ligands results in more functional PD-1H T-cells, a conclusion reached in 
the previous paper that I discussed. The authors note that existing studies have found an increase in 
PD-L1 and PD-L2 expression in APCs infected by HIV, even though the mechanism remains 
unknown. On this basis, the researchers hypothesize that HIV is able to “disrupt the generation 
and/or activation of HIV-specific T-cells by attenuating/disrupting Ag presentation via upregulation 
of PD-L1/2 expression on APCs and hence signaling through PD-1 on T-cells” (Muthumani, et al. 
2011). To study this hypothesis, the authors disrupted the interaction between PD-1 and PD-L1 
using PD-L1 small interfering RNA (siRNA), molecules that can prevent the receptor-ligand 
interaction using complementary base pairing. They also sought to show that APCs in HIV infected 
humans express higher levels of PD-1 than uninfected donors.  
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8: Increased PD-L1/2 on PBMCs from HIV-infected patients. A: Gating of infected 
monocytes from HIV-1 positive patients. B: PD-L1 expression on infected monocytes 
compared with controls. C: Relative expression of PD-L1/2 analyzed by RT-PCR. Fold 
change represents relative expression in comparison to negative control sample. D: 
Flow plots showing expression of CD80 and CD86, with isotype control (gray line) on 
monocytes. E: Bar graphs show upregulation of CD80 and CD86 on uninfected (thin 
lines) and infected (thick lines) monocytes. F: Gating strategy for isolating pDCs and 
mDCs. G: Expression of PD-1 in mDC and pDC populations.  (Muthumani, et al. 2011) 
 By using flow cytometry, Figure 8A identifies that levels of PD-1 ligands increase in HIV 
infected patients. Their gating strategy for separating HIV-specific cells was on the basis of whether 
they were HIV-1 p24 Gag+ or HIV-1 p24 Gag-. In the second gating, cells were separated on the basis 
of positivity for CD4 and CD14; a double positive indicated an antigen presenting cell, specifically a 
monocyte. In the upper dot plots, among the cells that were specific for HIV, there are cells with a 
much higher level of PD-L1 and PD-L2 expression compared to the monocytes from uninfected cells 
(lower panel of 8A). 
Similarly, Figure 8B shows 
the difference in PD-L1 mean 
fluorescence intensity (MFI), 
between monocytes in HIV-
positive and HIV-negative 
individuals. As can be seen, 
with a p value of 0.0001, the 
PD-1 levels in HIV-positive 
monocytes are far higher 
than in HIV-negative 
individuals. The authors 
wanted to determine if the 
effect was a result of higher 
gene expression, so they 
carried out reverse-
transcription polymerase 
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chain reaction (RT-PCR). Figure 8C shows the relative gene amounts in the samples from infected 
patients and the uninfected (u.i.) control. The labeled fold change refers to the amount of PD-L1 or -
L2 DNA present in relation to the uninfected control. Since the u.i. was taken as baseline 1 fold, all 
the patient samples (1-8) are expressed in folds of the uninfected sample. As can be seen, both PD-
L1 and PD-L2 expression was increased in most patients compared to the u.i. control. From both 
Figures 8A and B, it is clear that HIV significantly upregulates PD-L1 and PD-L2 expression on 
monocytes.  
 To further study the effect of HIV on APCs, the authors separately examined two subsets of 
dendritic cells, myeloid (mDC) and plasmacytoid (pDC). Figures 8 D-G show the results of this 
experiment. Muthumani et al. stained the samples to identify CD80 and CD86 (costimulatory 
markers) in the monocytes. Figure 8D shows how almost all CD14+ monocyte cells expressed the 
two receptors. The authors found that there was no significant difference in marker expression 
between infected and non-infected individuals (Figure 8E). This established that the HIV virus was 
not changing the expression of co-stimulatory molecule and weakening the APC activation of T-cells 
in that way. The researchers studied the effects of HIV on PD-L1 expression in both subsets of 
dendritic cells and found that it was largely responsible for the suppression of the T-cell response. 
Figure 8G shows the results of this specific experiment: the mean PD-1 expression for both mDCs 
and pDCs in infected vs. health patients. It becomes clear that the infection HIV results in a 
significant rise in PD-L1 expression in both dendritic cell subsets, but especially in pDCs.  
 At this point, the lab had successfully demonstrated a rise in PD-L1. However, the question 
remained whether this upregulation had an effect on T-cells. To determine this, the authors 
correlated their data of PD-1 with PD-L1 expression on cells within the same sample using flow 
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9. A: Correlation between PD-1 
expression in T-cells with PD-L1 
expression in APCs. B and C: Direct 
inverse correlation between PD-L1 
expression and CD4 cell counts (B) and 
IFN-γ production (C).  
(Muthumani, et al. 2011) 
cytometry. As can be seen in Figure 9A, the expressions of both 
receptors are directly correlated with a positive slope. In Figure 
9B, they show that, as PD-L1 levels increased, counts of CD4+ 
cells, including the critical T-helper cells, decreased with a 
negative slope. Finally, the researchers found an even steeper 
decline (slope more negative than Fig. 9B) of IFN-γ secretion. 
This directly shows the link between upregulation of PD-L1 and 
increased T-cell exhaustion, which decreases the ability of the 
patient’s immune system to fight the virus. 
 Muthumani et al. then sought to collect more 
information about this effect: whether it could be observed in 
multiple cell populations and suppressed. Using known gene 
sequences for PD-L1 and 2, they researchers created target 
siRNA for both proteins. Using pools of three to five PD-L1 and 
PD-L2 specific siRNAs and a non-specific siRNA control, the 
authors could see whether they could stop the upregulation of 
PD-1 ligands. Furthermore, they could also see if the prevention 
of the PD-L1 and 2 upregulation could decrease the inhibition of T-cells. Figure 10A shows the 
Western blots of protein samples along with the β-actin control gel. The effects of the PD-L1 siRNA 
clone sequences 1 and 2 are shown. It seems that clone 1 has no difference in band darkness to the 
negative control or siRNA control, indicating no effect on PD-L1 expression. The relative increase in 
darkness of the control siRNA band is correlated to the corresponding increased darkness in the β-
acting control for the same lane. This means that perhaps the amount of sample loaded was 
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10: PD-L1 mediated functional suppression of HIV-specific CD8 T-cells. A:  
Western Blot for PD-L1 content of whole cell lysate with β-actin controls. B: 
FACS plot with PD-L1 expression on CD14
+ 
cells 5 days after siRNA 
treatment. C and D: ELISPOT analysis of IFN-γ production by Gag-specific (C) 
or Env-specific (D) monocytes when cultured with PD-L1-blocking siRNA or 
antibodies. E: Blockade of PD-L1 can restore immune cytokine production 
after PD-L1 silencing. Env-stimulated samples were tested for cytokine 
responses and are shown.   (Muthumani, et al. 2011) 
accidentally more and is not suggestive of an actual increase in PD-L1 expression for the control. 
The important aspect of this figure is the drop in PD-L1 expression when the siRNA clone 2 is used. 
Presumably, the siRNA clone 2 bound to mRNA for PD-L1 expression, blocking its translation into 
the receptor protein.  
 In Figure 10B, the results are confirmed through a different medium: flow cytometry. As 
can be seen, PD-L1 expression in monocytes remains fairly constant throughout the various controls 
and siRNA clone 1, but for siRNA clone 2, the expression drops to 2.0%! This confirms the 
conclusion that the use of siRNA 
clone 2 is able to stop the 
upregulation of PD-L1. The authors 
then had to study whether or not 
this limiting of PD-L1 expression has 
an effect on cytokine expression by 
T-cells. Figures 10C and D show the 
levels of IFN-γ specific to HIV group-
specific antigen (or gag- antigen 
within the core protein of the virus) 
or envelope (env- antigen on the 
external protein coat) measured by 
ELISPOT after stimulation in culture. 
ELISPOT, an adaptation of the ELISA 
(enzyme-linked immune sorbent 
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11: Increased T-cell proliferation after PD-L1 silencing. A and B: Mixed cells 
incubated in medium only, siRNA control only, or PD-L1 siRNA. Flow cytometry 
carried out displaying CFSE as a function of CD8 on CD3 lymphocytes. C: 
Proliferative responses for Gag (top) and Env (bottom) with value for siRNA 
control subtracted. (Muthumani, et al. 2011) 
assay), is a procedure using monoclonal antibodies, specific for the cytokine of interest, that are 
conjugated to a fluorescent tag. The cytokines are captured on a special membrane and following 
addition of color sensitive reagents, the color change and spots are used to measure the number of 
colonies producing the given cytokine and quantify the amount being produced.  
Figures 10 C and D both show a very similar trend of cytokine production. The culture of 
siRNA-silenced monocytes and monocytes with blocking antibodies for PD-L1 produced the highest 
level of IFN-γ for either HIV antigen. This indicates that both are effective in reducing T-cell 
exhaustion. siRNA stops the upregulation of PD-L1 in the first place, compared to the anti-PD-L1 
antibodies that only prevent the PD-1/PD-L1 interaction. Finally, Figure 10E shows the impact of PD-
L1 siRNA broken down specifically by cell type: TC cells (CD3/CD8), TH cells (CD3/CD4), and dendritic 
cells (CD14). For every single cell type, the introduction of siRNA resulted in an almost uniform 3-
fold increase in secretion of pro-inflammatory cytokines (IL-2, IFN-γ, and IL-12). Furthermore, 
secretion of the anti-inflammatory cytokine, IL-10, decreased by the same degree, indicating the 
revival of lymphocyte and dendritic cell function, as well as the increase of general inflammatory 
effects.  
The lab similarly shows 
that the use of siRNA increases 
the proliferation of T-cells. 
Figure 11A illustrates how, 
through the use of decreasing 
CFSE concentration as a marker 
for increased T-cell division, 
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12: Correlation between PD-L1 and 
PI3K/Akt Pathway. A and B: Proteins from 
infected human cells analyzed for Akt and 
pAkt using ELISA (A) and Western Blot (B). C: 
U937 cells infected with HIV and stained 
with anti-PD-L1. The effect of drug 
treatment (thin line) on expression of PD-L1 
in HIV infected cells (thick line) is displayed. 
Gray line represents the isotype control. 
(Muthumani, et al. 2011) 
the PD-L1 siRNA results in a three to four fold increase for the gag-specific T-cells (A) and up to a 4.4 
fold increase for the env-specific T-cells (B). The data is alternately displayed according to the 
percentage of cells containing CFSE (greater percentage implies that T-cells have divided, conferring 
daughter cells with CFSE at lesser concentrations). As can be seen, both gag-specific (top) and env-
specific (bottom) CD8 and CD4 cells showed an increase in cell proliferation when PD-L1 expression 
was blocked by siRNA.  
 Having established conclusively that HIV viral infection 
does upregulate the expression of PD-L1 and PD-L2 and that 
siRNA or antibody interference with PD-1/PD-L1 expression 
and/or binding is effective in reviving T-cell activity, the 
authors wanted to explore the mechanism through which this 
occurs. They hypothesized that the PI3K/Akt pathway played a 
strong role in the upregulation of PD-L1 by HIV. As can be 
seen in Figure 12, when PI3K is activated by its ligands and co-
receptors, it phosphorylates Akt. To study the role of this 
mechanism in HIV’s effects (1), the researchers used a PI3K 
specific signaling inhibitor, LY294002, and an Akt inhibitor, Akt 
inhibitor-IV. Muthumani et al. harvested proteins from 
cultured U937 (a model monocyte cell line) cells periodically 
following infection with HIV. Using ELISAs, these samples were 
then analyzed for Akt and pAkt. They found that from 12-
hours post-infection onwards, there was a large jump in 
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amount of phosphorylated Akt (pAkt), while the level of regular Akt rises only slightly during the 
time period (Figure 12A). This indicates that the levels of non-phosphorylated Akt are not changing, 
confirmation that the increase in pAkt is not due to increased expression but rather increased 
phosphorylation of existing Akt. This conclusion is verified in the Western blot results of Figure 12B. 
Levels of Akt are not significantly changed, however, at 12 hours from infection, the amount of pAkt 
is much higher than at 6 hours. This indicates a role of the pAkt process in HIV infection. The 
researchers are able to confirm that this pAkt process is involved in specifically the PD-L1 process 
when inhibition of PI3K and Akt both lead to decrease in number of cells expressing high levels of 
PD-L1. The HIV+DMSO control shows two cell population groups: one with lower PD-L1 (uninfected 
cells, thin lines) and one with higher PD-L1 (infected cells, bold line). In the presence of either 
pathway inhibitor, the infected cell population is shifted left, representing moderate levels of PD-L1 
expression (Figure 12C). This data is directly indicative that the PI3K/Akt pathway is the mechanism 
through which PD-L1 is upregulated by HIV in antigen presenting cells.  
 In Figure 12B, the researchers should have included the control bands of β-actin to provide 
the context for analyze the darkness of each lane. Also, the data in C does not necessarily prove 
that the PI3K/Akt pathway is the only way in which PD-L1 is upregulated by HIV. There is a high 
likelihood that other mechanisms are involved as well. This is indicated by the fact that in the 
presence of signaling inhibitors, levels of PD-L1 don’t return to uninfected levels.  Granted, this 
could be impossible due to the inability to block the effects of HIV in every single cell. An ideal next 
step to confirm the scope of the PI3K/Akt signaling pathway would be to flood the culture with the 
signaling inhibitors and see whether PD-L1 amounts are comparable to that of uninfected cells. The 
authors did indeed carry out this step (data not shown). They conducted an assay in which they 
slowly increased the concentration of both inhibitors. The levels of PD-L1 activity slowly decrease 
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13: Signaling pathway of PD-1/PD-L1 (Muthumani, et al. 2011) 
until they become zero. This indicates that the PI3K/Akt pathway is critical for HIV’s upregulation of 
PD-L1 in antigen presenting cells.  
 In conclusion, Muthumani et al. make significant progress in explaining the inability of HIV+ 
immune systems to mount complete effector responses. In part, this can be explained by the 
unusual role of HIV in not only exploiting PD-1 expression but also upregulating PD-L1 expression. 
The paper cites that little is known about the function and distribution of PD-L1 and PD-L2, limiting 
how we understand the receptor/ligand interaction. It is understood that the loss of TH cells is one 
of the main debilitating aspects of HIV infection, a primary reason that the body’s own immune 
system is crippled. However, this emerging research shows how HIV uses alternate pathways as 
well, such as expression of PD-L1 on antigen-presenting cells, to weaken the immune system in 
different ways. There is scope for therapeutic development in this regard, which will be covered 
more in the synthesis section. 
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Discussion and Synthesis 
 The combination of the three papers provides a broad overview of the role of HIV and other 
viruses in the weakening of the immune system, more specifically on T-cell exhaustion during 
chronic infection.  PD-1 is a necessary part of the immune system and is involved in regulation of 
the immune response by balancing the need to prevent auto-immunity with maintaining basic 
immune efficacy. However, viral infection seems to utilize this pathway to weaken the immune 
system. All three papers center around the basic premise that programmed death-1 plays a 
significant role in limiting the T-cell response. Each of the papers takes a similar experimental 
response to the problem: first to identify the correlation (if any) between viral infection and 
expression of PD-1, and then to study co-surface molecules and the extent and ways in which the 
PD-1 expression affects T-cell exhaustion (measured by cytokine expression, proliferation, or 
apoptosis). While the papers’ collective results can be aggregated as a model, there are significant 
areas of difference.  
The first paper, by Petrovas et al, studies the role of PD-1 and CD57, both surface molecules, 
in T-cell survival during chronic viral infection. During infection, PD-1 is significantly upregulated on 
CD8 T-cells. The authors find that PD-1 expression is linked to a higher prevalence of both 
spontaneous and C95/Fas mediated apoptosis. The paper shows that PD-1 and CD57 are oppositely 
linked to T-cell survival. In fact, expression of CD57 was an indication of resistance to apoptosis. 
However, strangely enough, the researchers find that there is no connection between PD-1 
expression in T-cells and secretion of cytokines, in particular IL-2, IFN-γ, and TNF-α. This was directly 
contradicted in both the following papers where the same cytokines were tested, but resulted in 
opposite conclusions.  
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The second paper studied the role of PD-1 and CTLA-4 in mediating the immune system and 
regulating T-cell functionality in hepatitis C infection. The researchers study the expression of PD-1 
and CTLA-4 and found that, for HCV, PD-1 and CTLA-4 are significantly upregulated in hepatic 
lymphocytes but not in blood lymphocytes.  In patients with acute infection, these expression levels 
are comparable in the blood as well. However, this similarity ended when the disease progressed to 
chronic stage as the upregulated cells were almost exclusively present in the liver. While this was 
surprising at early stages, it later seemed normal that the virus was suppressing T-cells the most in 
its primary area of infection. For HCV, the liver was the site of T-cell exhaustion. However, for HIV, 
the bloodstream was the area of action and therefore was the site of PD-1 upregulation.  
The second and third papers explored the potential therapeutic implications of this 
upregulation. Nakamoto et al, studied the effects of an individual and combined PD-1 and CTLA-4 
blockade on T-cell proliferation and cytokine expression. They found that a dual antibody blockade, 
not just anti-PD-1 alone, was required to both reverse T cell dysfunction and renew cell 
proliferation.  This paper established a biochemical interaction mechanism between PD-1/CTLA-4 
and CD28, a co-receptor. They mention that the PI3K/Akt is involved in this process but they don’t 
elaborate further. This segues well into the study conducted in the third paper two years later.  
Muthumani et al carry out a well-designed study to identify the exact mechanism through 
which HIV acts to induce T-cell exhaustion. However, they take a very unique approach to the 
problem. Rather than study the upregulation of PD-1 on T-cells as the previous papers did, the 
authors study the role of HIV in upregulating PD-L1’s ligands (PD-L1 and PD-L2) on antigen-
presenting cells. They hypothesize that HIV infection of dendritic cells results in a rise in PD-L1 and 
PD-L2 levels and that this increase is responsible for the T cell exhaustion that is exhibited during 
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chronic infection. As described earlier in this paper, they are able to prove this upregulation and 
then link it to decreasing cytokine levels and T cell counts.  
This agreement between the Nakamoto et al and Muthumani et al contradicts the 
assertions made in the first paper that the PD-1H phenotype doesn’t influence cytokine secretion. 
This finding, by Petrovas et al, is weakened by evidence from multiple research papers showing the 
role PD-1 has on T-cell exhaustion, including cytokine suppression. The sheer number of papers that 
contradict the findings of Petrovas et al, only lends further credence to this conclusion. 
To move from the effects of PD-1 and PD-L1 to practical application, Muthumani et al, take 
the novel approach of using siRNA to stop the translation of the PD-L1 and L2 RNA into protein. This 
silencing does significantly increase the levels of cytokine secretion and T cell proliferation. 
However, the most effective treatment seemed to be the use of blocking antibodies to prevent the 
binding of PD-1 to its ligands. The authors then prove the conclusions of Nakamoto et al by linking 
the PI3K/Akt pathway to the expression of PD-L1 in antigen presenting cells. They use inhibitors of 
PI3K and Akt and find that HIV is unable to upregulate PD-L2 in APCs without the activation of this 
pathway.  
The model that the three papers together provide has a significant implication on treatment 
options for HIV. It establishes the way through which HIV causes CD8 T-cell exhaustion: not only 
due to lack of sufficient CD4 T-cell support, but also through upregulation of the PD-L1/2 and PD-1 
pathway due to the increase in expression of the both the receptor and its ligands. The research 
shows that HIV, as well as other viruses, has been able to exploit the body’s natural regulatory 
mechanisms in order to weaken the immune system and further replicate.  
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The papers’ focus on chronic viruses shows that, despite their common use of PD-1, many of 
the viruses act through slightly different activation mechanisms. Some involve CTLA-4 as a co-
receptor in the activation pathway while others require molecules such as T-cell immunoglobulin 
mucin domain-3 (Tim-3), a T-cell surface receptor. Regardless, once these mechanisms of action are 
better understood, they could be a target for therapeutic intervention. The second and third papers 
show how use of anti-receptor antibodies (such as PD-1) or siRNA specific to receptors or ligands 
can stop the activation of the pathway. Elite controllers, those individuals that are genetically able 
to control viral replication without medication, have been reported to be able to maintain their 
immune response by preventing the upregulation of PD-1 (Baker, et al. 2009). This research sheds 
light on the ability of the individuals self-sufficiently fight the virus and resist its effects on T-cells. 
Possible therapies for HIV could mimic this advantage that elite controllers have and minimize 
damage of the virus.   
During these infections, HIV or others (such as CMV, HCV, or LCMV), the effect of the virus 
on individual cells is devastating. To control the spread of viral infection, it is crucial that the body is 
able to mount a strong immune response. However, the opposite often happens. In an HIV 
infection, as CD4 T-cells die, the Tc cells would ideally step in and fight the infection. But, at the 
same time, CD8 T-cells start to weaken and become anergic due to the interaction between 
upregulated PD-1 and PD-L1 and L2. This makes HIV immunologically crippling. Treatment with 
siRNA or anti-PD-1/PD-L1 blockades, in addition to HAART, would allow the patient to fight the 
disease on two fronts. HAART would slow down viral replication while, concurrently, the siRNA or 
blockade would reverse the inhibition of CD8 T-cells, allowing the body to fight the disease 
naturally.  
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Future Experiments 
 While the three papers fit in well together in terms of new knowledge of PD-1 activity, there 
is some key experimentation to be done that would take this knowledge forward.  
A potential first step would be to explore the role of CTLA-4 and CD28 in other viral 
infections, not just HCV, to identify whether these effects are unique or uniform for other major 
viruses including HIV, SIV, and HCMV. As can be seen from Figure 1, CTLA-4 is present in the same 
signaling pathway. As a result, it probably has a role in mediating the T-cell exhaustion. I would use 
the same methods used by Nakamoto et al when they test for a correlation between CTLA-4 and 
PD-1 upregulation for HCV and apply them to HIV and other viruses as well. The other two papers 
establish that PD-1 is upregulated; however none of them study whether CTLA-4 expression 
increases along with PD-1 for non-HCV cases.  
To further study the upregulation of CTLA-4, I would take chronic patients and, using flow 
cytometry, test their blood for the percentage of CD8 cells that express CTLA-4 to see whether this 
receptor is upregulated too. The paper by Muthumani et al showed that use of PD-L1 antibody 
blockades was the most effective way to revive the T-cell population. If CTLA-4 does have a role in 
this regulation in HIV too, then the inclusion of a dual PD-L1/CTLA-4 blockade would be so much 
more effective, especially if CD28 promoted the T-revival. If we can identify a constant role for 
CTLA-4 expression in various viruses, we could use that information to create better therapies to 
combat this inhibition of T-cells.  
I also want to explore the role of PI3K/Akt in the PD-1 upregulation processes. From these 
three papers, we can conclude that this signaling pathway is responsible for the upregulation of 
both PD-1 in T-cells and PD-L1 and PD-L2 in antigen-presenting cells. In order to better understand 
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this mechanism, we would need to identify whether that is the only path through which these 
receptors and ligands are upregulated. This could be done through blocking of various common 
immunological signaling mechanisms, with siRNA or antibody blockades, and, through RT-PCR, 
ELISPOT, or Western Blot, observing whether upregulation still takes place in cell culture. 
Another interesting step would be to establish a model for developing medication for these 
diseases. SIV (simian immunodeficiency virus), a cousin of HIV, might be a potential target in this 
case. SIV can be characterized in the same way researchers study HIV. If they can establish that, like 
HIV, SIV upregulates PD-1 in culture conditions, researchers should attempt to identify key co-
receptors involved in the signaling process in a human-like system.  This information could further 
help in developing therapies to block the role of these molecules in a simian model. 
Using this information, we could develop siRNA and antibody receptor-blockades specific to 
SIV, using similar procedures used by Nakamoto et al and Mutumani et al. This would allow us to 
move from in-vitro to in-vivo experimentation. Since a simian model is very complex, it could 
provide a good basis from which to establish effectiveness and safety of therapy. One such concern 
of using siRNA or antibody blockades to prevent PD-1 activation is that that T-cells might become 
too uninhibited, leading to increased autoimmunity. It is important to remember that PD-1 and 
CTLA-4 are crucial regulatory molecules. Nakamoto et al cite that knock -out mice for these genes 
suffer from lupus-like autoimmune conditions or eventual fatal lymphoproliferation (Nakamoto, et 
al. 2009). As such, the PD-1 pathway should not be completely silenced.  
A similar problem is seen with the role of the PI3K/Akt signaling pathway. Muthumani et al 
showed that the suppression of the signaling molecules completely prevented the upregulation of 
PD-L1. While this seems like an easy therapeutic intervention, it is important to note that this 
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pathway has major roles in other processes in the body. Inhibiting its function could have disastrous 
effects on other body systems. Therapies that strike this balance between preventing over or under 
expression could be achieved within an animal model to ensure that it was safe and effective before 
starting clinical trials in humans.  
In conclusion, like most other HIV and other chronic viral infection research that is 
emerging, these conclusions require extensive further exploration and development to have greater 
potential as therapeutic paths. The role of the ‘HIV controller’ needs to be studied further, by 
identifying if the prevention of PD-1 upregulation is a key factor leading to their resistance. If so, the 
prevention of PD-1 upregulation during chronic viral infection could be a central means through 
which patients could be treated. In addition to standard therapy, such as the use of HAART, this 
treatment could prevent the weakening of a patient’s immune system, allowing the body to 
naturally help fight HIV itself. This research is thus a crucial link in the fight against HIV/AIDS and, 
pending further study, has tremendous therapeutic potential. 
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